Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

tenofovir disoproxil

This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.

ViiV starts trial of HIV-preventing injections for women

ViiV starts trial of HIV-preventing injections for women

can defend against the spread of the virus as well as daily dosing with Gilead’s oral pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil).

Latest news

  • People at-risk of HIV in England could get PrEP from September People at-risk of HIV in England could get PrEP from September

    The study of Gilead's pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil) - which was approved by the EMA last year - follows a pilot that saw the drug prevent

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    The fixed dose combination of integrase strand inhibitor bictegravir with the two active ingredients in Descovy - emtricitabine and tenofovir alafenamide - met its main objective of non-inferiority to ViiV Healthcare's ... The drug is an upgrade to

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF

  • Gilead's Truvada cleared for HIV prevention in EU Gilead's Truvada cleared for HIV prevention in EU

    The EU approval of Truvada (emtricitabine and tenofovir disoproxil) for PrEP comes four years after the drug got a green light from the US FDA for reducing sexual transmission of HIV ... Gilead is in the process of rolling out a replacement product for

  • ViiV takes two-drug cocktail for first-line HIV into phase III ViiV takes two-drug cocktail for first-line HIV into phase III

    three-drug regimen based on Tivicay and Gilead Sciences' double NRTI drug Truvada (tenofovir disoproxil fumarate/emtricitabine). ... HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and

More from news
Approximately 5 fully matching, plus 42 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Quick links

Infographics

Multimedia